Novo Nordisk Gears Up for EASD as CagriSema Data Meets a Skeptical Market
Published on 09/27/2026 at 06:31 | Editorial boerse-global.de
Novo Nordisk enters a pivotal stretch this week, with the annual meeting of the European Association for the Study of Diabetes (EASD) opening Monday and running through October 2. The Danish drugmaker will put 44 scientific presentations on the table in Milan, and investors are zeroing in on one question above all: can the company's next-generation obesity and diabetes pipeline hold its ground against mounting competition?
CagriSema Takes Center Stage
The headline attraction is CagriSema, the investigational combination therapy for which Novo Nordisk is unveiling Phase 3 results. The pre-released numbers from two registration trials have already set a high bar. In REIMAGINE 5, the 1.0 mg/1.0 mg dose produced 12.4% weight loss in adults with type 2 diabetes after 60 weeks of treatment, against 9.1% for a 5 mg dose of rival tirzepatide. Non-inferiority was also achieved on HbA1c reduction. In the second trial, REDEFINE 9, overweight or obese adults shed 21% of their body weight over 68 weeks compared with placebo.
Those Phase 3 figures, disclosed on September 21, are what reignited the debate on the stock. Novo Nordisk has said it will now align the regulatory pathway for the type 2 diabetes indication with authorities — a step that carries growing urgency, since the market has grown impatient with strategic announcements and is demanding hard evidence of future market leadership.
The competitive gap with tirzepatide is the crux of the investment case. A roughly three-percentage-point edge on weight loss gives the Danes a visible advantage, but one that still has to prove itself in the regulatory arena. If the company can show that clinical benefit comes without a trade-off in tolerability, it strengthens the foundation for the post-semaglutide era. If regulators and physicians see the therapeutic distance as marginal, future premium pricing comes under pressure.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Partnerships Extend the Technology Base
Beyond the clinic, management is pushing additional collaborations to broaden its technology platform. On Friday, Novo Nordisk signed a global license and cooperation agreement with Swedish firm Nanexa covering its PharmaShell delivery technology. The deal spans up to five development programs for long-acting injections, with Nanexa eligible for payments of up to EUR 1.165 billion — EUR 615 million of which covers upfront, development and regulatory milestones — plus low single-digit royalties. Novo Nordisk takes the lead on global development and commercialization.
The company is also leaning on digital tools: a partnership with Anthropic is meant to integrate models such as Claude Science into research and software development, speeding up the discovery of new active substances.
A Stock Searching for a Floor
On the trading floor, the share is hunting for stability after a bruising stretch. The stock closed Friday with a modest gain of 0.2% at EUR 34.05, yet remains down 23% since the start of the year. Attention has shifted from past growth rates toward the durability of the forward pipeline.
Not everyone is convinced. On Tuesday, CFRA downgraded Novo Nordisk's US depositary receipts from Hold to Sell, setting a price target of USD 38. Reuters reported that market participants have found the company's longer-term growth ambitions sobering; Evan Seigerman of BMO noted that annual revenue growth of 3.6% is already priced in. Add to that intensifying price competition, looming patent expirations, and management's own admission that its 2030 targets carry uncertainty and do not constitute a binding financial forecast. Should market growth flatten earlier than expected, the operating margin faces a stress test.
What Hangs on the Milan Data
The bull case rests on Novo Nordisk steering CagriSema swiftly through approval and establishing it as a superior next-generation therapy. That would underpin long-term ambitions of more than DKK 150 billion in risk-adjusted pipeline revenue by 2035, alongside a goal of launching more than five products with multi-blockbuster potential by 2030.
For now, the confirmation of clinical superiority is what matters most. As long as regulatory progress on CagriSema stays on track and the efficacy data hold up in direct comparison, Novo Nordisk has a potent counterweight to competitive pressure. But if confidence in pricing power falters, or if regulatory steps toward approval slip, the stock's downtrend is likely to persist. The details presented in Milan — spanning semaglutide, CagriSema and zenagamtid — will serve as the next proving ground for the pipeline's credibility.
Ad
Novo Nordisk Stock: New Analysis - 27 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
